Up to date, all currently available gene signatures have failed to discriminate oestrogen receptor (ESR1)-negative/HER2-negative breast cancer with poor prognosis from those with relatively good outcome (Desmedt et al, 2008). This evidence concerns the gene ESR1 and breast cancer.